Serological biomarkers identify responders to Crohn's disease therapy
2020
University of Groningen, Groningen, Netherlands
Anti-tumor necrosis factor (TNF) therapy is effective in inducing remission in Crohn's disease in 60% of patients. No serological biomarkers are available, which can predict response to anti-TNF. The researchers aimed to investigate serological markers of collagen turnover reflecting tissue inflammation as predictors of response to anti-TNF. In 2 retrospective observational cohorts, Four markers were measured in serum and compared with standard C-reactive protein in patients with active Crohn's disease who started therapy. The results show that the response to anti-TNF therapy within the first 14 weeks of treatment can be predicted based on baseline levels of basement membrane marker C4M. This marker could be used as a biomarker for response to anti-TNF and could aid in early therapy decision-making.
Serological biomarkers of tissue turnover identify responders to anti-TNF therapy in Crohn's disease: a pilot study
Wouter T. van Haaften
Added on: 10-26-2022
[1] https://journals.lww.com/ctg/Fulltext/2020/09000/Serological_Biomarkers_of_Tissue_Turnover_Identify.9.aspx
